-transparent.png){kind=logo}
The single agent activity of methotrexate in non-seminomatous germ cell tumours (NSGCT), and thus the rationale for its inclusion in combination regimens, has never been documented clearly. We have therefore reviewed all patients with NSGCT treated in this hospital from 1967 to 1970. Seventeen patients were identified who had a rising HCG excretion and who were treated with methotrexate alone as first line chemotherapy. Nine patients (53%) obtained a partial remission and a further seven patients a reduction in HCG production that was less than one log. Methotrexate is an active agent in testicular germ cell tumours and should be of particular value in treating CNS disease where intrathecal treatment may be required.
D B Smith, and
G J Rustin, and
R Hitchins, and
K D Bagshawe, and
P Hoskins
January 1987,
Medical oncology and tumor pharmacotherapy,
D B Smith, and
G J Rustin, and
R Hitchins, and
K D Bagshawe, and
P Hoskins
January 1991,
European journal of cancer (Oxford, England : 1990),
D B Smith, and
G J Rustin, and
R Hitchins, and
K D Bagshawe, and
P Hoskins
November 2006,
Clinical radiology,
D B Smith, and
G J Rustin, and
R Hitchins, and
K D Bagshawe, and
P Hoskins
May 2014,
Der Pathologe,
D B Smith, and
G J Rustin, and
R Hitchins, and
K D Bagshawe, and
P Hoskins
January 1985,
The British journal of surgery,
D B Smith, and
G J Rustin, and
R Hitchins, and
K D Bagshawe, and
P Hoskins
September 1982,
Lancet (London, England),
D B Smith, and
G J Rustin, and
R Hitchins, and
K D Bagshawe, and
P Hoskins
May 2009,
Critical reviews in oncology/hematology,
D B Smith, and
G J Rustin, and
R Hitchins, and
K D Bagshawe, and
P Hoskins
February 2006,
The Journal of pathology,
D B Smith, and
G J Rustin, and
R Hitchins, and
K D Bagshawe, and
P Hoskins
January 1984,
Acta radiologica. Oncology,
D B Smith, and
G J Rustin, and
R Hitchins, and
K D Bagshawe, and
P Hoskins
January 1985,
Journal of the Royal Society of Medicine,
